Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus IODIXANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus IODIXANOL.
HYPAQUE-CYSTO vs IODIXANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iodixanol is a nonionic, iso-osmolar iodinated contrast agent that attenuates X-rays, allowing visualization of vascular structures and organ parenchyma. It does not bind to or interact with specific receptors.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous injection of 270-350 mg iodine/kg (0.5-1.0 mL/kg of 270 mg I/mL solution) for CT; 300-400 mg iodine/kg for angiography. Administer as bolus or infusion per procedure.
None Documented
None Documented
Clinical Note
moderateIodixanol + Metformin
"The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin."
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 10-12 hours, requiring dose adjustment and monitoring.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily renal: approximately 97% of the administered dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Less than 3% is excreted in feces via biliary elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent